Werewolf Therapeutics Director Executes $198,309 in Scheduled Stock Sales
Luke Evnin, a director at Werewolf Therapeutics, Inc. (NASDAQ: HOWL), has completed a series of stock sales totaling $198,309. These transactions occurred between April 30 and May 4, 2026, following a predetermined Rule 10b5-1 trading plan. The liquidations took place against a backdrop of recent share price volatility and significant corporate res…